Drugs https://doi.org/10.1007/s40265-018-0922-6 LEADING ARTICLE Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab Pratima Chowdary The Author(s) 2018, corrected publication June/2018 Abstract Replacement therapy with missing factor Pharmacokinetic parameters were inﬂuenced by binding to (F) VIII or IX in haemophilia patients for bleed manage- the target (TFPI), demonstrating target mediated drug ment and preventative treatment or prophylaxis is standard disposition. A trend towards decreasing bleeding tendency of care. Restoration of thrombin generation through novel was observed and this preventative effect is being studied mechanisms has become the focus of innovation to over- in Phase 2 studies with additional data gathered to improve come limitations imposed by protein replacement therapy. our understanding of the therapeutic window and potential Tissue factor pathway inhibitor (TFPI) is a multivalent for thrombosis. Kunitz-type serine protease inhibitor that regulates tissue factor (TF)-induced coagulation through a FXa-dependent feedback inhibition of the TF.FVIIa complex in plasma and Key Points for Decision Makers on endothelial surfaces. Concizumab is a monoclonal, humanised antibody, speciﬁc for the second Kunitz domain Restoration of thrombin generation is increasingly of TFPI that binds and inhibits FXa, abolishing the inhi- considered as a therapeutic intervention to overcome bitory effect of TFPI. Concizumab restored thrombin the limitations of protein replacement therapy. generation in FVIII and FIX deﬁcient plasmas and Anti-TFPI monoclonal antibodies restore thrombin decreased blood loss in a rabbit haemophilia model. Phase generation by abolishing the inhibitory effect of 1 single and multiple dose escalation studies in haemo- TFPI on the initiation of coagulation. philia patients demonstrated a dose dependent decrease in TFPI levels and a pro-coagulant effect with increasing A dose-dependent pro-coagulant effect has been d-dimers and prothrombin fragment 1 ? 2. A dose noted in Phase 1 clinical studies with anti-TFPI dependent increase in peak thrombin and endogenous antibodies with potentially a decrease in bleeding thrombin potential was observed with values in the normal tendency, which requires conﬁrmation in larger range when plasma TFPI levels were nearly undetectable. studies over a longer duration. A few haemophilia patients in the highest dose cohorts with complete inhibition of plasma TFPI showed a decreased ﬁbrinogen concentration with normal levels of 1 Introduction anti-thrombin and platelets and no evidence of thrombosis. 1.1 Haemophilia The original version of this article was revised: Due to Figure 1 caption update. Haemophilia A and B are inherited bleeding disorders & Pratima Chowdary characterised by a deﬁciency or absence of factor (F) VIII email@example.com and FIX, respectively. The incidence of haemophilia A is 1 1 in 5000 male live births, and that of haemophilia B is 1 in Katharine Dormandy Haemophilia and Thrombosis Centre, 30,000 . The FVIII and FIX Subcommittee of the Royal Free Hospital, Pond Street, London NW3 2 QG, UK P. Chowdary International Society of Thrombosis and Haemostasis has treatment administration to be modiﬁed to their personal recommended the use of plasma levels for classifying the circumstances, to improve treatment outcomes, potentially severity of haemophilia. Three patient groups are recog- increasing treatment burden [11–13]. nised based on their plasma levels: severe haemophilia Current management of bleeding in patients with inhi- (FVIII or FIX \ 1 IU/dL), moderate haemophilia (FVIII or bitors includes treatment with bypassing agents, either FIX between 1 and 5 IU/dL) and mild haemophilia (FVIII recombinant activated factor VIIa (rFVIIa) or activated or FIX between 6 IU/dL and 40 IU/dL) . The classiﬁ- prothrombin complex concentrate (APCC) [10, 14]. The cation usually predicts the bleeding phenotype and patients mechanisms underpinning their haemostatic efﬁcacy are with a severe disorder present with recurrent spontaneous based on restoration of thrombin generation through path- and trauma-related bleeding . In an untreated state, ways that potentially contribute a minimal amount of recurrent and spontaneous bleeding into joints and muscles thrombin under normal conditions [15–17]. Besides bleed results in disability, with bleeding into vital organs or from management, they are used for secondary and tertiary a mucosal surface being the most common cause of death prophylaxis, but they are less effective when compared to . FVIII and FIX prophylaxis in non-inhibitor patients and have been associated with occasional episodes of throm- 1.2 Modern Haemophilia Treatment—Principles bosis [18–21]. and Limitations 1.3 Haemophilia Treatment—New Approaches Modern haemophilia treatment includes replacement ther- apy with missing FVIII or FIX with correction of bleeding Restoration of thrombin generation through novel mecha- tendency and a near normal life span [1, 4]. Besides nisms has become the focus of innovation in the last decade management of bleeds with replacement therapy, regular to overcome some of the limitations imposed by protein intravenous infusion either by parents or patients on aver- replacement therapy. Two broad approaches that restore age between two-to-four times per week improves the thrombin generation are in clinical trials. The ﬁrst approach bleeding phenotype. This practice of preventive treatment includes a bi-speciﬁc antibody, which acts as a FVIIIa or prophylaxis has been the cornerstone of haemophilia mimetic bridging FIXa and FX with the generation of FXa. treatment for the last ﬁve decades. Prophylaxis, by The FXa generation is regulated by substrate availability increasing the baseline level to 1% or greater aims to rather than through inhibition of the bi-speciﬁc antibody convert a severe bleeding tendency to a moderate pheno- [22, 23]. The second approach results in reduced function type, thereby decreasing the number of spontaneous bleeds of natural inhibitors. This is achieved either through a . decrease in activity of anti-thrombin (AT) or tissue factor Different types of prophylactic regimens are recognised pathway inhibitor (TFPI). AT is the principle serine pro- based on the timing of prophylaxis initiation. In primary tease inhibitor regulating the common, initiation and prophylaxis, it is commenced before or after the ﬁrst joint ampliﬁcation pathways , whereas TFPI is a dominant bleed, but before the second joint bleed. In secondary inhibitor of the initiation pathway [25, 26]. prophylaxis it is initiated after two or more joint bleeds but before the onset of joint disease, and tertiary prophylaxis is started after the onset of joint disease [6–8]. Primary pro- 2 Tissue Factor Pathway Inhibitor—Structure phylaxis or early secondary prophylaxis results in near and Distribution normal joint health and normal life span. Limitations of current treatment include: implementa- 2.1 Structure tion of prescribed prophylactic regimens , development of inhibitory antibodies that makes treatment ineffective TFPI is a multivalent Kunitz-type serine protease inhibitor , requirement for regular intravenous infusions, difﬁ- that regulates TF-induced coagulation  through an culties with venous access, patient compliance, cost of FXa-dependent feedback inhibition of the FVIIa. TF drugs, progression of joint disease, risk of intracranial complex, which initiates coagulation [27, 28]. TFPI was bleeding, and modest treatment goals, all of which impact cloned in 1988 and the amino acid sequence shows a on quality of life. Further, regular prophylaxis results in negatively charged amino acid terminus, three tandem oscillation of factor levels and coagulation potential, and Kunitz-type inhibitory domains (K1, K2, and K3), and a while this achieves a minimum trough level of 1% or positively charged carboxyl terminus . The historical greater with a decrease in the number of spontaneous discovery, its role in coagulation regulation and disorders bleeds to single ﬁgures and potentially to zero, it does not of coagulation have been extensively reviewed [30–32]. prevent traumatic bleeds. Thus, individual patients require Anti-TFPI Monoclonal Antibodies for Haemophilia Treatment Multiple isoforms of TFPI have been described sec- temporally, and localisation is crucial for limiting blood ondary to alternative mRNA splicing events, and the two loss without compromising blood ﬂow through excessive important isoforms include TFPI alpha (TFPIa) and TFPI clot formation [41, 42]. Inadequate thrombin generation beta (TFPIb). TFPIa is a 276-residue glycoprotein secondary to inherited or acquired deﬁciency of coagula- with an acidic amino terminus followed by three Kunitz tion factors results in a bleeding diathesis . Replace- domains and a basic carboxy terminus. In TFPIb, the car- ment therapy or bypass agents restore thrombin generation boxy terminus contains a glycosylphosphatidylinositol and clot formation and improve the bleeding tendency (GPI) anchor replacing the K3 domain . The K1 and [10, 44]. K2 domains bind and inhibit FVIIa and FXa, respectively. Following tissue injury, the extrinsic pathway or initia- The K3 domain has no known inhibitory function [30, 31]. tion pathway forms the extrinsic tenase complex (TF.FVIIa) and provides the initial FXa for the pro- 2.2 Distribution thrombinase complex. The intrinsic pathway or ampliﬁca- tion pathway becomes the source of additional FXa fol- Endothelial cells and megakaryocytes are the main cells lowing inhibition of extrinsic tenase complex by TFPI producing TFPI [32, 33]. TFPIb is the predominant TFPI [27, 45]. Pro-thrombinase complex comprimised of FXa isoform expressed on endothelium where its association is bound to activated cellular surfaces in the presence of its maintained via a GPI anchor [34, 35]. TFPIa is secreted by co-factor FVa, converts prothrombin to thrombin (common human endothelial cells and is present in plasma. TFPI pathway). Thrombin mediates platelet activation and ﬁbrin levels are increased two- to four-fold following heparin deposition enabling blood clot formation [41, 42]. infusion where TFPIa is the main isoform . This hep- The inhibitory activity of TFPI is initiated by the arin-releasable pool may be bound to cell-surface gly- binding of the K2 domain to FXa resulting in its inhibition cosaminoglycans through its basic C-terminal region, and the formation of a binary TFPI.FXa complex. This is although the exact mechanism is not well described . closely followed by binding of the K1 domain to FVIIa in TFPIa is also produced by megakaryocytes and stored the TF.FVIIa binary complex to form a quaternary complex within quiescent platelets. Platelet TFPI is available for that inhibits further activation of FX. The rate-limiting step release following platelet activation when it can exhibit its in these sequential reactions is the inhibition of FXa and inhibitory activity . At the site of vascular injury, local not the inhibition of TF.FVIIa [28, 45]. Protein S binds the TFPI concentrations appear to increase through the release K3 domain of TFPIa, localising it to membrane surfaces of TFPI from accumulating platelets within the thrombus and enhancing the inhibition of FXa by the K2 domain. and this release is facilitated by dual activation with col- This is particularly relevant at physiological concentrations lagen and thrombin . of TFPI [46–48]. Further, TFPIa is also able to inhibit FXa- The mean plasma circulating TFPI concentration in activated FVa and platelet FVa formed in the early stages normal individuals is 1.6–2.5 nM or * 70 ng/mL [30, 37]. of clot initiation resulting in inhibition of the pro-throm- In plasma, 80% of TFPI is predominantly bound to low- binase complex at physiological levels. This interaction is density lipoproteins (LDL), and is carboxy-terminal trun- mediated through a high-afﬁnity exosite interaction cated, with levels of the former having an impact on the between the basic region of TFPIa and the FV acidic TFPI levels . The remaining 20% of TFPI circulates in region . the free form deﬁned by the presence of the K3 domain. It In summary, TFPI inhibits the activity of two major consists of either FL-TFPIa contributing most to the anti- protease–co-factor complexes: extrinsic tenase complex coagulant activity or carboxy-terminal truncated TFPI . generating FXa and early pro-thrombinase complex that The platelet TFPI pool exclusively consists of FL-TFPIa, includes FXa activated FVa . Attenuation of this the amount equal to the circulating active full length TFPI. inhibition results in restoration of thrombin generation. The At baseline, the plasma TFPI pool is around 3% of the total relative contribution of the two pathways in this restoration vascular TFPI pool. Readily available mature TFPI appears is not known. to consist of 95% GPI-anchored TFPIb . The potential for using TFPI inhibition to manage hae- mophilia A and B was conceived as early as 1991. In an in vitro laboratory study of haemophilic plasma, a pro- 3 Rationale for Inhibition of TFPI coagulant effect was demonstrated by shortening of the dilute thromboplastin time following the addition of anti- The blood haemostatic response initiated following dam- TFPI antibody . A subsequent study tested the clinical age to the vasculature results in thrombin generation, pla- effect of a polyclonal anti-TFPI IgG antibody in rabbits telet activation and aggregation, enabling clot formation with anti-FVIII antibody-induced haemophilia. The [39, 40]. This response is localised both spatially and bleeding time shortened signiﬁcantly from 26 to 11 min P. Chowdary but did not normalise (normal mean bleeding time in non- medicinal product. The studies include explorer 1, a Phase 1 haemophilia rabbits: 5 min). Further, correction of coagu- single-dose escalation study ; explorer 3, a Phase 1 lation tests was seen at doses of anti-TFPI antibody that multiple dose study ; explorer 4, a Phase 2 proof of were lower than doses required to correct bleeding ten- concept multiple-dose study in inhibitor patients (Clini- dency . Additionally, in a mouse model of calTrials.gov Identiﬁer: NCT03196284); and explorer 5, a haemophilia, an anti-TFPI polyclonal antibody decreased Phase 2 proof of concept study in non-inhibitor patients blood loss in a tail clip assay. Blood loss continued to (ClinicalTrials.gov Identiﬁer: NCT03196297). BAY- decrease beyond complete inhibition of plasma and 1093884 from Bayer is a monoclonal antibody against both endothelial TFPI pools, suggesting a putative role for Kunitz-1 and Kunitz-2, presently recruiting to Phase 1 sin- inhibition of platelet TFPI released at the site of injury gle- and multiple-dose escalation studies (ClinicalTrials.gov . Identiﬁer: NCT02571569) [54, 55]. Similarly, PF-06741086 from Pﬁzer is a monoclonal antibody against the Kunitz-2 domain recruiting to multiple-dose studies in non-inhibitor 4 Anti-TFPI Antibodies in Clinical Trials patients (ClinicalTrials.gov Identiﬁer: NCT02974855) . Three monoclonal antibodies against TFPI are currently in various phases of clinical trials and are illustrated in Fig. 1. 5 Concizumab (mAb 2021) Concizumab (mAb-2021) from Novo Nordisk is a mono- clonal, humanised IgG4 antibody speciﬁc for the K2 domain Following the initial characterisation of TFPI, site-directed TM of TFPI . The explorer studies are a series of clinical mutagenesis conﬁrmed that the K2 domain was required trials conducted with concizumab as the investigational for efﬁcient binding and inhibition of FXa, and both the K1 Fig. 1 TFPI mechanism of action and inhibition by anti-TFPI b Inhibition of FXa and FVIIa by TFPI. c Binding of the different antibodies. a Tissue factor (TF) based initiation of coagulation and Kunitz (K) domains by the various anti-TFPI antibodies generation of FXa by the extrinsic tenase complex (FVIIa.TF.FX). Anti-TFPI Monoclonal Antibodies for Haemophilia Treatment and K2 were required for inhibition of FVIIa.TF activity. K2 domain of human TFPI deﬁning the antibody-binding Alterations of the active-site residues of the K3 domain had epitope are all conserved in rabbit TFPI. Rabbits were no signiﬁcant effect on either function. The production and induced with haemophilia with an anti-factor VIII anti- characterisation of concizumab were detailed by Hilden body. Administration of concizumab signiﬁcantly reduced et al., and a summary is provided below . cuticle bleeding in haemophilia rabbits when anti-TFPI antibody was administered 30 min prior to induction of 5.1 Isolation and Characterisation bleeding and blood loss was also reduced when adminis- tered within 5 min of onset of bleeding. No effect of In brief, human recombinant TFPI was isolated from a concizumab was observed when administered 15 or 30 min baby hamster kidney cell line. Mice were subsequently after induction of bleeding . A dose-dependent effect immunised with full-length TFPI and hybridomas were was noted in the amount of blood loss and duration of generated from mice splenic cells with aid of myeloma effect. Efﬁcacy was also demonstrable after subcutaneous cells and supernatant screened for anti-TFPI antibodies. administration. The anti-TFPI antibodies were subsequently screened for their reactivity against human TFPI. Antibodies of interest were selected based on their ability to inhibit FXa and form 6 Concizumab Clinical Studies a functional quaternary complex. Subsequently, the anti- body was humanised and cloned into a human IgG4 format. 6.1 Phase 1 Clinical Study X-ray crystallography of concizumab demonstrated an extensive overlap between the binding epitope of con- The ﬁrst in human Phase 1 study (explorer 1) was con- cizumab and predicted FXa contact region of the K2 ducted in patients with severe haemophilia A and B and domain, providing a structural basis for the inhibition. healthy volunteers. The study design and outcomes are Concizumab also demonstrated high afﬁnity binding to described in brief below . both soluble (K2 domain and FL-TFPI) and cell surface bound (human umbilical vein endothelial cells) TFPI. 6.2 Study Design 5.2 Ex Vivo Efﬁcacy The study was a multicentre, randomised, double-blind, placebo-controlled, single-dose, dose-escalation trial. In The attenuation and abrogation of TFPI activity by con- each dose cohort, trial participants were randomised 3:1 to cizumab has been demonstrated by the lack of TFPI inhi- receive a single dose of concizumab (n = 3) or placebo bition of FXa generation in puriﬁed systems and cell-based (n = 1). Following drug administration, patients were seen assays. This effect was also demonstrated in a modiﬁed regularly, and samples were collected for pharmacokinetic prothrombin assay, in which tissue factor (innovin or (PK), pharmacodynamics (PD), and safety assessments. thromboplastin) concentration was adjusted to give a clot Initial dosing was performed in healthy volunteers and time of * 200 s with normal plasma. A dose-dependent when pre-deﬁned criteria were reached, the drug was decrease in clotting was observed following the addition of administered to haemophilia patients, thus restricting the concizumab. Concizumab restored thrombin generation number of haemophilia patients required to conduct of the and this was demonstrated in FVIII immune depleted study. The switching criteria were consistent elevation of plasma supplemented with platelets at 150 9 10 /L. d-dimers and/or prothrombin fragment 1 ? 2 above the Thrombin generation was activated with low doses of normal reference range for 24 h or more in two or more innovin (0.12 pM TF) and dose-dependent changes were healthy volunteers, and/or when a maximum intravenous observed with increased peak, increased area under curve, (IV) dose of 250 lg/kg and a maximum subcutaneous (SC) and shorter lag times. In whole blood samples from healthy dose of 1000 lg/kg was administered to healthy volun- volunteers rendered haemophilic with sheep anti-FVIII teers. Randomised haemophilia patients were in either the IgG, a dose-dependent decrease in clotting time and max- IV cohorts (single doses included: 250 , 1000, 3000 and imum thrombus formation to within normal ranges was 9000 lg/kg) or in SC cohorts (doses included 1000 and observed when tested by thromboelastography when spiked 3000 lg/kg). with concizumab. 6.3 Endpoints 5.3 In Vivo Efﬁcacy The primary endpoint was safety and secondary endpoints The in vivo efﬁcacy of concizumab has been demonstrated included PK and PD parameters. Table 1 describes the in a rabbit cuticle bleeding model as the amino acids in the various parameters . P. Chowdary Table 1 Study endpoints a a Safety endpoints Pharmacokinetics (PK) Pharmacodynamics (PD) Adverse events over 43 days PK endpoints—area under curve (AUC), D-dimer and prothrombin fragment maximum plasma concentration (C ), 1 ? 2 concentrations max Clinical assessments including ECG clearance (CL), half-life (t ), mean absorption Free TFPI in plasma by ELISA (i.e. Local injection-site reactions time, volume of distribution at steady state, TFPI not bound to concizumab, Lab assessments—routine and for evidence of bioavailability, and time to maximum Asserachrom TFPI) disseminated intravascular coagulation (PT, concentration Residual TFPI functionality— aPTT, ﬁbrinogen concentration, platelet count, Plasma concizumab concentrations (ELISA assay detection of FXa generation with protein C, S & AT activity) for both free concizumab & concizumab chromogenic assay, S2222; Anti-concizumab antibodies by ELISA technique complexed with TFPI) Chromogenix) aPPT activated partial thromboplastin time, ECG electrocardiogram, TFTI tissue factor pathway inhibitor, PT prothrombin time Blood samples for PK and PD analysis were collected at baseline, at 0 (i.e. completion of injection), 5, 15, and 30 min; 1, 4, 8, 12, 24, 36, and 48 h; and 3, 4, 5, 6, 7, 10, 14, 21, and 43 days post-dosing. Blood samples from 5 and 15 min were omitted when the drug was administered subcutaneously 6.3.1 Results—Safety 6.3.3 Results—Pharmacodynamics Fifty-two subjects (28 healthy male volunteers and 24 Two assays were used to assess the impact of concizumab. haemophilia patients: 21 with haemophilia A and 3 with The ﬁrst was a quantitative assay to determine the total haemophilia B) were enrolled and randomised to treatment amount of TFPI by ELISA in the plasma that does not bind or placebo. During the trial, there were no reports of seri- to the drug. A dose-dependent decrease in concizumab ous adverse events (SAEs). Five of the other reported AEs free-total TFPI concentration was observed. The levels were possibly or probably treatment related, including two were low for up to 2 weeks in the highest dose cohort. The in the placebo group and three in concizumab group. The second assay was a functional assay that measured FXa latter included a single episode of a short segment of generation as a function of TFPI. The residual functional superﬁcial thrombophlebitis in a healthy volunteer in the TFPI levels decreased with the total TFPI levels. A dose- 1000 lg/kg, SC cohort. The patient presented with skin dependent pro-coagulant response as assessed by d-dimer tenderness 5 days post-drug administration and an ultra- and prothrombin fragment 1 ? 2 levels was seen. The sound conﬁrmed a short segment of phlebitis. Injection site steepest increase was observed in healthy volunteers fol- reactions were seen in a few patients. lowing IV administration. Importantly, haemophilia In the haemophilia patients randomised to the higher SC patients showed similar d-dimer response compared with dose cohorts (1000 or 3000 lg/kg), transient elevation of healthy volunteers when they received an approximately troponin T was noted in 3 patients with no signiﬁcant ECG 36-fold higher dose of concizumab. abnormalities. Similarly, a couple of haemophilia patients randomised to the higher IV dose cohorts (1000 or 6.4 Thrombin Generation and Concizumab 3000 lg/kg) halved their ﬁbrinogen concentration with no concurrent decrease in protein C, protein S, AT, or platelet Ex vivo spiking of samples from patients with haemophilia count. A and B with concizumab displayed a dose-dependent increase in peak thrombin and endogenous thrombin 6.3.2 Results—Pharmacokinetics potential (ETP) with shortening of the lag time. The inﬂuence on peak thrombin was more marked when com- Concizumab was detected in plasma up to 43 days after pared with ETP. A similar effect was seen in samples taken dosing. There were no differences in the PK proﬁles from healthy volunteers dosed with concizumab . between healthy volunteers and haemophilia subjects. PK proﬁles were consistent with target-mediated drug dispo- 6.5 Clinical Study—Multiple Dose sition (TMDD) in which binding of concizumab to TFPI inﬂuenced drug distribution, elimination, and plasma The ﬁndings in explorer 1 study, were replicated in concentration. explorer 3, which was a placebo-controlled, multiple-dose, dose-escalation study where concizumab was administered SC . A dose-dependent decrease in concizumab free- total TFPI and procoagulant effect were noted. Further, a Anti-TFPI Monoclonal Antibodies for Haemophilia Treatment dose-dependent increase in peak thrombin and ETP was can decrease with increasing dose [61, 62]. In this context, seen, and in the higher dose cohort, thrombin generation it is important to identify the drug- and target-speciﬁc parameters were within normal range. parameters that inﬂuence exposure–response relationships, and patient-speciﬁc characteristics that account for inter- 6.6 Clinical Study—Phase 2 Proof of Concept subject PD variability . Both explorer 1 and explorer 3 demonstrated a decreasing 7.2 TMDD and Concizumab bleeding tendency with higher concizumab doses, but the trials were not designed to demonstrate proof of efﬁcacy To understand the impact of TMDD on the PK proﬁle of . explorer 4 and 5 will explore the ability of con- concizumab, several experiments were undertaken on cizumab to decrease bleeding tendency in patients with Cynomolgus monkeys . A classical TMDD model was severe haemophilia A and B with and without inhibitors, used for analysing PK, which included compartments for respectively. Due to the signiﬁcant impact of TMDD, both standard drug disposition and target binding. Fol- concizumab will be administered daily, and to decrease lowing subcutaneous administration, bioavailability of treatment burden, it will be administered SC . The concizumab was estimated at 93%, absorption half-life was starting dose in the trials is 0.15 mg/kg (150 lg/kg) with estimated at 72 h and terminal half-life was dependent on dose escalation to a maximum of 0.25 mg/kg (250 lg/kg). plasma concentration. At low levels of concizumab, non- The bleed frequency will be observed for a period of linear clearance was the most important elimination route, 24 weeks in the ﬁrst instance, followed by a 12-month secondary to TFPI binding. Maximum elimination rate extension phase. Patients will continue to administer FVIII (V ) was estimated at 11 lg/kg/h. When levels reached max or rFVIIa for management of bleeds. In addition to over 100 lg/mL, conventional linear clearance dominated demonstrating efﬁcacy of concizumab, the trials could and was estimated at 0.14 mL/h/kg . potentially shed light on the level of TFPI inhibition TMDD was conﬁrmed in the Phase 1 studies and, at low required for decreasing the bleeding tendency. concizumab concentrations, binding to TFPI was the dominant inﬂuence resulting in faster nonlinear clearance; whereas at higher levels, a slower more linear clearance 7 Target-Mediated Drug Disposition (TMDD) was noted . 7.1 TMDD—Deﬁnition and Description 7.3 Challenges of Pro-Coagulant Therapies The PK proﬁle of small drug molecules is typically linear, A major challenge for the widespread use of pro-coagulant with dose increases resulting in a proportional increase in therapies is the lack of data around the overlap between the plasma concentration with binding to receptors having a therapeutic window, where bleed prevention is achieved, minimal effect. Non-linear PK is also common, where and the toxicity window where there is a potential there is a lack of proportional increase in plasma concen- increased risk of thrombosis. Under baseline conditions of tration with increases in drug dose. This non-proportional regular prophylaxis, such overlap is unlikely. Further, the response impacts on the relationship between drug con- interactions between replacement therapy and bypass centration and desired pharmacological effect and unde- agents administered for bleed management, and the novel sired toxicity . The term TMDD has been used to pro-coagulant therapies need to be investigated urgently. In describe non-linear PK, where a signiﬁcant proportion of this context, transient hypercoagulability is to be expected, the drug is bound with high afﬁnity to the pharmacological but there are limited data on the magnitude, duration, and target, relative to the dose administered . clinical impact of this hypercoagulability. Further, there The PK consequences of TMDD are pronounced when has been a tendency towards a one-size-ﬁts-all approach binding to the target contributes to signiﬁcant elimination when evidence from thrombin generation studies shows a of the drug. Further, if the binding is saturable it results in wide range of values both in the normal population and different concentration–time proﬁles for different individ- patients with haemophilia A and B. ual doses . With saturable target binding, at low drug Further, the in vivo mechanisms that underpin clot for- concentration, administration of increasing doses is asso- mation and thrombin generation need to be elucidated. ciated with an apparent decreasing steady-state volume of Elevated d-dimers represent a pro-coagulant state, but distribution until the target is saturated. Following satura- borderline elevations could also potentially represent tion of the target binding, a limiting value is reached with a exaggerated basal coagulation with no impact on either long terminal elimination half-life. Therefore, when target bleeding or thrombotic tendency . binding contributes signiﬁcantly to clearance, clearance P. Chowdary Society on Thrombosis and Haemostasis. Thromb Haemost. Concizumab clinical trials have shown that the doses 2001;85(3):560. selected for the Phase 2 studies inhibit most of the plasma 3. Larsson SA. Life expectancy of Swedish haemophiliacs, pool and a proportion of the intravascular pool, and one 1831-1980. Br J Haematol. 1985;59(4):593–602. could speculate that this might provide protection against 4. Peyvandi F, Garagiola I, Young G. The past and future of hae- mophilia: diagnosis, treatments, and its complications. Lancet. thrombosis as most of the intravascular pool is localised at 2016;388(10040):187–97. the endothelial surface. Further, there are no routine tests 5. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-ﬁve available for monitoring the restoration of thrombin gen- years’ experience of prophylactic treatment in severe haemo- eration in a meaningful fashion. Additional data on the philia A and B. J Intern Med. 1992;232(1):25–32. 6. Ljung R, Gretenkort Andersson N. The current status of pro- correlation between measures of thrombin generation and phylactic replacement therapy in children and adults with clinical effect are required. haemophilia. Br J Haematol. 2015;169(6):777–86. 7. Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with haemophilia A or B in the United Kingdom who were not infected with HIV. 8 Conclusion Blood. 2007;110(3):815–25. 8. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den In summary, the advent of pro-coagulant therapies aiming Berg HM, Srivastava A. Deﬁnitions in haemophilia: communi- to restore thrombin generation through exploitation of non- cation from the SSC of the ISTH. J Thromb Haemost JTH. 2014;12(11):1935–9. dominant coagulation pathways raises exciting possibilities 9. Richards M, Williams M, Chalmers E, Liesner R, Collins P, of not only decreased treatment burden but also improved Vidler V, Hanley J. A United Kingdom Haemophilia Centre patient outcomes. These possibilities need to be tempered Doctors’ Organization guideline approved by the British Com- against potential thrombotic risks and unanticipated risks, mittee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with which need to be addressed in forthcoming trials and post- severe haemophilia A. Br J Haematol. 2010;149(4):498–507. marketing surveillance studies. 10. Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th Acknowledgments I would like to thank the staff and patients of edition). UK Haemophilia Centre Doctors Organization. Br J Katharine Dormandy Haemophilia and Thrombosis Centre for their Haematol. 2013;160(2):153–70. participation in trials of anti-TFPI monoclonal antibodies. 11. Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with Compliance with Ethical Standards haemophilia. JAMA J Am Med Assoc. 2012;308(14):1452–9. 12. Collins PW. Personalized prophylaxis. Haemophilia. Funding No external funding was used in the preparation of this 2012;18(Suppl 4):131–5. manuscript. 13. Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20(5):607–15. Conﬂict of interest PC reports, grants and personal fees from Pﬁzer, 14. Hedner U, Lee CA. First 20 years with recombinant FVIIa grants, personal fees and non-ﬁnancial support from Bayer, personal (NovoSeven). Haemophilia. 2011;17(1):e172–82. fees and non-ﬁnancial support from Baxalta (Shire), grants, personal 15. Giansily-Blaizot M, Schved JF. Recombinant human factor VIIa fees and non-ﬁnancial support from CSL Behring, grants, personal (rFVIIa) in haemophilia: mode of action and evidence to date. fees and non-ﬁnancial support from NovoNordisk, grants, personal Ther Adv Hematol. 2017;8(12):345–52. fees and non-ﬁnancial support from Swedish Orphan Biovitrum AB 16. Hoffman M, Monroe DM. 3rd The action of high-dose factor (Sobi), personal fees from Freeline, personal fees from Roche, outside VIIa (FVIIa) in a cell-based model of hemostasis. Disease-a- the submitted work. month DM. 2003;49(1):14–21. 17. Varadi K, Tangada S, Loeschberger M, Montsch P, Schrenk G, Open Access This article is distributed under the terms of the Ewenstein B, Turecek PL. Pro- and anticoagulant factors facili- Creative Commons Attribution-NonCommercial 4.0 International tate thrombin generation and balance the haemostatic response to License (http://creativecommons.org/licenses/by-nc/4.0/), which per- FEIBA((R)) in prophylactic therapy. Haemophilia. mits any noncommercial use, distribution, and reproduction in any 2016;22(4):615–24. medium, provided you give appropriate credit to the original 18. Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coag- author(s) and the source, provide a link to the Creative Commons ulant complex prophylaxis in haemophilia with inhibitors. N Engl license, and indicate if changes were made. J Med. 2011;365(18):1684–92. 19. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophy- lactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric References patients with haemophilia A and inhibitors. Haemophilia. 2007;13(3):249–55. 1. Mannucci PM, Tuddenham EG. The haemophilias–from royal 20. Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus genes to gene therapy. N Engl J Med. 2001;344(23):1773–9. NovoSeven in haemophilia patients with inhibitors. Semin 2. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild Thromb Hemost. 2013;39(7):772–8. C, Ingerslev J. Deﬁnitions in haemophilia. Recommendation of 21. Chai-Adisaksopha C, Nevitt SJ, Simpson ML, Janbain M, Konkle the scientiﬁc subcommittee on factor VIII and factor IX of the BA. Bypassing agent prophylaxis in people with haemophilia A scientiﬁc and standardization committee of the International or B with inhibitors. Cochrane Database Syst Reviews (Online). 2017;9:441. Anti-TFPI Monoclonal Antibodies for Haemophilia Treatment 22. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab Prophy- 41. Monroe DM, Hoffman M. What does it take to make the perfect laxis in Haemophilia A with Inhibitors. N Engl J Med. clot? Arterioscler Thromb Vasc Biol. 2006;26(1):41–8. 2017;377(9):809–18. 42. Butenas S, van’t Veer C, Mann KG. ‘‘Normal’’ thrombin gener- 23. Kitazawa T, Igawa T, Sampei Z, et al. A bispeciﬁc antibody to ation. Blood. 1999;94(7):2169–78. factors IXa and X restores factor VIII hemostatic activity in a 43. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated haemophilia A model. Nat Med. 2012;18:1570. thrombin generation measurement in clotting plasma. Patho- 24. Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of physiol Haemost Thromb. 2003;33(1):4–15. antithrombin in haemophilia A or B with RNAi therapy. N Engl J 44. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Med. 2017;377:819–28. Guidelines for the management of haemophilia. Haemophilia. 25. Chowdary P, Lethagen S, Friedrich U, et al. Safety and phar- 2013;19(1):e1–47. macokinetics of anti-TFPI antibody (concizumab) in healthy 45. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, volunteers and patients with haemophilia: a randomized ﬁrst Miletich JP, Broze GJ Jr. Functional signiﬁcance of the Kunitz- human dose trial. J Thromb Haemost. 2015;13(5):743–54. type inhibitory domains of lipoprotein-associated coagulation 26. Hilden I, Lauritzen B, Sorensen BB, et al. Hemostatic effect of a inhibitor. Nature. 1989;338(6215):518–20. monoclonal antibody mAb 2021 blocking the interaction between 46. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates FXa and TFPI in a rabbit haemophilia model. Blood. inhibition of the tissue factor pathway by tissue factor pathway 2012;119(24):5871–8. inhibitor. Proc Natl Acad Sci USA. 2006;103(9):3106–11. 27. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, 47. Ndonwi M, Tuley EA, Broze GJ Jr. The Kunitz-3 domain of Miletich JP. The lipoprotein-associated coagulation inhibitor that TFPI-alpha is required for protein S-dependent enhancement of inhibits the factor VII-tissue factor complex also inhibits factor factor Xa inhibition. Blood. 2010;116(8):1344–51. Xa: insight into its possible mechanism of action. Blood. 48. Wood JP, Ellery PE, Maroney SA, Mast AE. Protein S is a 1988;71(2):335–43. cofactor for platelet and endothelial tissue factor pathway inhi- 28. Baugh RJ, Broze GJ Jr, Krishnaswamy S. Regulation of extrinsic bitor-alpha but not for cell surface-associated tissue factor path- pathway factor Xa formation by tissue factor pathway inhibitor. way inhibitor. Arterioscler Thromb Vasc Biol. J Biol Chem. 1998;273(8):4378–86. 2014;34(1):169–76. 29. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Jr. 49. Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast Cloning and characterization of a cDNA coding for the lipopro- AE. Tissue factor pathway inhibitor-alpha inhibits prothrombi- tein-associated coagulation inhibitor shows that it consists of nase during the initiation of blood coagulation. Proc Natl Acad three tandem Kunitz-type inhibitory domains. J Biol Chem. Sci USA. 2013;110(44):17838–43. 1988;263(13):6001–4. 50. Nordfang O, Valentin S, Beck TC, Hedner U. Inhibition of 30. Broze GJ Jr, Girard TJ. Tissue factor pathway inhibitor: structure- extrinsic pathway inhibitor shortens the coagulation time of function. Front Boisci (Landmark edition). 2012;17:262–80. normal plasma and of haemophilia plasma. Thromb Haemost. 31. Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant 1991;66(4):464–7. activities for a single protein. Arterioscler Thromb Vasc Biol. 51. Erhardtsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner 2016;36(1):9–14. U, Nordfang O. Blocking of tissue factor pathway inhibitor 32. Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue (TFPI) shortens the bleeding time in rabbits with antibody factor pathway inhibitor. Blood. 2014;123(19):2934–43. induced haemophilia A. Blood Coagul Fibrinolysis. 33. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. 1995;6(5):388–94. Cultured normal human hepatocytes do not synthesize lipopro- 52. Maroney SA, Cooley BC, Ferrel JP, et al. Absence of tein-associated coagulation inhibitor: evidence that endothelium hematopoietic tissue factor pathway inhibitor mitigates bleeding is the principal site of its synthesis. Proc Natl Acad Sci USA. in mice with haemophilia. Proc Natl Acad Sci USA. 1990;87(22):8869–73. 2012;109(10):3927–31. 34. Maroney SA, Ferrel JP, Pan S, White TA, Simari RD, McVey JH, 53. Eichler H, Kaan Kavakli PAK, Knoebl P, Windyga J, Jime´nez- Mast AE. Temporal expression of alternatively spliced forms of Yuste V, Friedrich U, Chowdary HP, et al. Mechanistic modeling tissue factor pathway inhibitor in mice. JThromb Haemost JTH. of the pharmacodynamic and pharmacokinetic relationship of 2009;7(7):1106–13. tissue factor pathway inhibitor-neutralizing antibody (BAY 35. Maroney SA, Mast AE. Expression of tissue factor pathway 1093884) in Cynomolgus Monkeys. AAPS J. inhibitor by endothelial cells and platelets. Transf Apheresis Sci. 2017;19(4):1186–95. 2008;38(1):9–14. 54. Gu JM, Zhao XY, Schwarz T, et al. Mechanistic modeling of the 36. Maroney SA, Haberichter SL, Friese P, Collins ML, Ferrel JP, pharmacodynamic and pharmacokinetic relationship of tissue Dale GL, Mast AE. Active tissue factor pathway inhibitor is factor pathway inhibitor-neutralizing antibody (BAY 1093884) in expressed on the surface of coated platelets. Blood. Cynomolgus Monkeys. AAPS J. 2017;19(4):1186–95. 2007;109(5):1931–7. 55. Paz P, Xie J, Aswad F. Antibody engineering of anti-tfpi bypass 37. Bajaj MS, Kuppuswamy MN, Manepalli AN, Bajaj SP. Tran- therapeutic BAY 1093884: isotype selection and sequence opti- scriptional expression of tissue factor pathway inhibitor, throm- mization. Blood. 2015;126(23):3496. bomodulin and von Willebrand factor in normal human tissues. 56. Rakhe S, Hett SP, Murphy JE, Pittman DD. An antibody to tissue Thromb Haemost. 1999;82(3):1047–52. factor pathway inhibitor (PF-06741086) in combination with recombinant factor VIIa increases hemostasis in haemophilia 38. Girard TJ, Tuley E, Broze GJ Jr. TFPIbeta is the GPI-anchored TFPI isoform on human endothelial cells and placental micro- plasma without excessive thrombin generation. Blood. somes. Blood. 2012;119(5):1256–62. 2016;128(22):2566. 39. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J 57. Lauritzen B, Hilden I. Concizumab promotes hemostasis via a Med. 2008;359(9):938–49. TF-FVIIa dependent mechanism as shown in a rabbit haemo- 40. Kim K, Hahm E, Li J, et al. Platelet protein disulﬁde isomerase is philia bleeding model. Blood. 2016;128(22):1401. required for thrombus formation but not for hemostasis in mice. 58. Waters EK, Sigh J, Friedrich U, Hilden I, Sorensen BB. Con- Blood. 2013;122(6):1052–61. cizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia P. Chowdary patients and healthy subjects measured by the thrombin genera- 62. Agerso H, Overgaard RV, Petersen MB, et al. Pharmacokinetics tion assay. Haemophilia. 2017;23(5):769–76. of an anti-TFPI monoclonal antibody (concizumab) blocking the 59. Lin JH. Dose-dependent pharmacokinetics: experimental obser- TFPI interaction with the active site of FXa in Cynomolgus vations and theoretical considerations. Biopharm Drug Dispos. monkeys after iv and sc administration. Eur J Pharm Sci. 1994;15(1):1–31. 2014;56:65–9. 60. Levy G. Pharmacologic target-mediated drug disposition. Clin 63. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Pharmacol Ther. 1994;56(3):248–52. Sturk A. Cell-derived microparticles circulate in healthy humans 61. Mager DE. Target-mediated drug disposition and dynamics. and support low grade thrombin generation. Thromb Haemost. Biochem Pharmacol. 2006;72(1):1–10. 2001;85(4):639–46.
– Springer Journals
Published: May 29, 2018